Skip to content
drillr.ai
Sign up

AKTS

Aktis Oncology, Inc.

NASDAQ · Healthcare · Biotechnology · US

$15.11
+0.33%
Ask drillr

  • Oct 1, 2026, 12:00 UTC

    Aktis Oncology initiated the Phase 1b BActinium-2 clinical trial of AKY-2519 in patients with non-small cell lung cancer and other B7-H3 expressing solid tumors.

    Source:

  • Aug 13, 2026, 00:00 UTC

    Aktis Oncology reported Q2 2026 collaboration revenue of $3.4 million, up from $1.6 million a year earlier, with a net loss of $24.1 million and cash and marketable securities of $517.3 million as of June 30, 2026.